BERTIS, Signed An MOU With Medical IP To Develop Bio AI Platform

- Develops Technologies To Predict And Prevent Diseases Using Heterogeneous Data Such As Bio And Medical Images
- Collaboration Between BERTIS' Quantitative Proteomics Technology And Medical IP's Medical Image Big Data-Based AI Technology
- "Expected To Lead The Development Of The Medical Environment And Advance The Era Of Precision Medicine"

< Photo: BERTIS-Medical IP's MOU Signing Ceremony (Left: Han Seung-man, CEO of BERTIS; Right: Park Sang-joon, CEO of Medical IP) >

Proteomics, which leads the diagnostic market, and AI, which represents digital healthcare, meet to open the future of precision medicine. 

BERTIS (CEO, Seung-man Han), a company that developed early diagnosis technology based on proteomics, announced on the 18th that it signed an MOU with Medical IP (CEO, Sang-Joon Park), a company that provides total solutions of medical AI, to develop a bio-duplex AI platform to predict and prevent diseases. 

This MOU can strengthen competitiveness through cooperation between two companies selected as innovation icons by the Korea Credit Guarantee Fund last year with the excellence in technology and the potential of entering overseas markets. Through the collaboration of BERTIS's leading technology in quantitative proteomics and Medical IP's medical image big data-based AI technology, the two companies agreed to develop a medical AI platform that evolved to the next level.

The bio-duplex AI platform is a technology that uses AI to comprehensively analyze bio-data on genome and proteome and medical image data obtained from CT, MRI, and X-ray. Through this, the two companies will develop technologies that can predict and prevent diseases. This technology is significant in that it predicts a disease before its outbreak, reducing the cost of treatment borne by the patient and improving the quality of life. 

This agreement is expected to predict diseases with higher accuracy if the data and technology of two companies in the different fields collaborate. Also, it plans to develop technologies to measure the risk of disease occurrence, discover new drug candidates for the prevention and treatment of diseases, and develop new drugs. 

Seung-man Han, the CEO of BERTIS said, "Predict and prevent diseases technology has been the goal in the medical field for a long time. I believe the collaboration of these two fields will develop the medical industry."

Sang-Joon Park, the CEO of Medical IP said, "It will present an innovative AI medical solution that can predict and prepare for diseases by analyzing them more closely and accurately based on various types of medical data. I expect precision medicine that provides personalized medical care shortly by combining the strengths and excellent technology of both companies can be provided."

Meanwhile, BERTIS succeeded in commercializing MASTOCHECK, an early breast cancer diagnosis solution through blood tests, and introduced it to major examination centers from last year. It is also developing technologies to diagnose cardiovascular diseases, pancreatic cancer, and ovarian cancer using its proteomics technique.